Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Doctor C. Ho (Boston, US)

Presentation thumbnail

Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM

Doctor C. Coats (Glasgow, GB)

Abstract Slides Video

Presentation thumbnail

Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation

Mr B. Van Driel (Amsterdam, NL)

Abstract Slides Video

Presentation thumbnail

Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis

Doctor A. Masri (Portland, US)

Abstract Slides Video

Access the full session

Session thumbnail

Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Congress Presentation

Patient case 2

Congress Presentation

Long-term efficacy of mavacamten on health status in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: results from long-term extension of the EXPLORER-CN trial

Congress Presentation

Integrated efficacy and safety analysis of mavacamten monotherapy in patients with obstructive hypertrophic cardiomyopathy

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources